wallflex™ duodenal stent system with anchor lock delivery system.
boston scientific peru s.a.c. -
starwalker.
intermedica solutions s.a.c. -
wallflex esophageal fully covered rmv stent system.
boston scientific peru s.a.c. -
lightwalker, marca: fotona.
futura medica odontologica sociedad anonima cerrada - f. m. o. s.a.c. -
wallflex™ esophageal partially covered stent system.
boston scientific peru s.a.c. -
wallflex™ esophageal fully covered stent system.
boston scientific peru s.a.c. -
wall mounted oxygen flowmeter.
etramed import sociedad anonima cerrada -
vyntus walk, marca: vyaire medical gmbh
hemocare s.a.c. -
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
ameluz
biofrontera bioscience gmbh - clorhidrato de ácido 5-aminolevulínico - keratosis, actinic; carcinoma, basal cell - agentes antineoplásicos - el tratamiento de la queratosis actínica de leve a moderada severidad en la cara y el cuero cabelludo (olsen grado 1 a 2; véase la sección 5. 1) y de campo cancerization en adultos. tratamiento superficial y/o nodular carcinoma de células basales inadecuados para el tratamiento quirúrgico, debido a la posible relacionada con el tratamiento de la morbilidad y/o mal resultado cosmético en adultos.